MedTrace Logo

Chantix for Treating Cocaine Dependence

NCT00567008 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2013-11-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether varenicline (Chantix), is effective for the treatment of cocaine dependence.

Conditions

  • Cocaine Dependence

Interventions

DRUG

varenicline

1.0 mg BID for 8 weeks

DRUG

placebo

placebo BID for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Jennifer G Plebani, PhD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567008 on ClinicalTrials.gov